Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

William Go

William Go


Academic history

William Go is the Senior Vice President and Head of Development at A2 Biotherapeutics, Agoura Hills, CA, which focuses on cell therapy. He was previously the Senior Medical Director and the Vice President of Clinical Development at Kite Pharma, Los Angeles, CA, as well as the US Medical Load in Global Development and Hematology/Oncology at Amgen, Thousand Oaks, CA.

Dr Go received his medical degree and PhD from the University of California, San Diego, CA, with his PhD being in biomedical sciences with a focus in immunology. He subsequently completed a residency in internal medicine and a fellowship in hematology/oncology at the University of California, San Diego, CA.

Speaking on chimeric antigen receptor (CAR) T-cells in lymphoma

Dr Go has previously developed novel immunocellular therapies for the treatment of cancer at Kite Pharma and led the ZUMA-1 pivotal study, leading to the approval of axicabtagene ciloleucel, the first CAR T-cell therapy approved in large B-cell lymphoma. He also played an instrumental role in the clinical development of panitumumab in colorectal cancer at Amgen, as well as identifying new predictive biomarkers as a Medical Director in Global Clinical Development.